BioVie Advances Parkinson’s Drug into Phase 3 with FDA End-of-Phase…

Event summary

BioVie plans to request an End-of-Phase 2 Meeting with the FDA to finalize its Phase 3 trial design for bezisterim in Parkinson’s disease.
The Phase 3 trial will use MDS-UPDRS Part III as the primary endpoint, with MDS-UPDRS Part I as a co-primary or secondary endpoint.
Phase 2 data suggest bezisterim may offer greater benefits for non-motor symptoms, particularly in patients with higher inflammation levels.
BioVie anticipates receiving formal FDA feedback on its proposed trial design before year-end.

The big picture

BioVie’s strategic shift toward a Phase 3 trial for bezisterim reflects growing interest in addressing both motor and non-motor symptoms in Parkinson’s disease, an area with significant unmet clinical needs. The company’s engagement with the FDA highlights the importance of regulatory alignment in advancing novel therapies, particularly for neurodegenerative diseases where endpoint selection remains challenging.

What we're watching

Regulatory Alignment: Whether the FDA will endorse BioVie’s proposed endpoint hierarchy, particularly the inclusion of MDS-UPDRS Part I for non-motor symptoms.
Trial Execution: The pace at which BioVie can enroll and complete the Phase 3 trial, particularly with an enrichment strategy targeting patients with elevated inflammation.
Therapeutic Potential: How bezisterim’s dual focus on motor and non-motor symptoms could differentiate it in the Parkinson’s disease market if Phase 3 results are positive.